Making Better Tomorrow, Bukwang Pharmaceutical. Bukwang R&D
NEWS

Bukwang Announces the result of SOL-804’s Phase 1 clinical trial

[March 30, 2022]

Bukwang Pharmaceutical Co., Ltd. announced the result of SOL-804’s phase 1 clinical trial through Dyna therapeutics, a subsidiary company of Bukwang. The result shows that it has similar pharmacokinetic properties with low-doses compared to the control group with high-doses. This study is for finding the right dosage of the drug and conducted in Seoul National Univ. hospital with 40 patients. It was compared to a control drug( Zytiga) in the safety, tolerance, and pharmacodynamics characteristics and was conducted in a way of randomized,...

R&D

Bukwang Announces the result of SOL-804’s Phase 1 clinical trial

[March 30, 2022]

Bukwang Pharmaceutical Co., Ltd. announced the result of SOL-804’s phase 1 clinical trial through Dyna therapeutics, a subsidiary company of Bukwang....

COMPANY

Bukwang Pharmaceutical Co., Ltd. was established on October 17th, 1960 and has since continued to produce excellent medications with the aim of improving global health for the last 55 years. Since Bukwang was listed in the Korea Stock Exchange...

Conterapharma
콘테라로고.jpg

Unlocking science for treating neurological disorders

   

Discover Bukwang

PRODUCTS
main_cg.jpg
|    ​Korean    |